Every Form 4 that Assembly Biosciences, Inc (ASMB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ASMB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASMB filings page.
ASSEMBLY BIOSCIENCES, INC. principal financial and accounting officer Jeanette M. Bjorkquist reported a small sale of 29 shares of common stock at $23.25 per share. The sale was executed solely to cover tax withholding on vested restricted stock units under a mandatory sell-to-cover rule, and she still holds 14,560 shares directly.
Gaggar Anuj reported acquisition or exercise transactions in this Form 4 filing.
Assembly Biosciences Chief Medical Officer Anuj Gaggar reported an equity compensation grant in the form of 14,000 shares of common stock at a price of $0.00 per share. These shares reflect restricted stock units that became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan on June 4, 2026.
The RSUs vest in four approximately equal installments on March 29, 2027, March 29, 2028, March 29, 2029, and March 29, 2030, assuming continuous service. Following this award and prior ESPP purchases, Gaggar now holds 42,688 common shares directly, indicating a routine compensation-related increase in ownership.
White Nicole S reported acquisition or exercise transactions in this Form 4 filing.
Assembly Biosciences reported that Chief Manufacturing Officer Nicole S. White received a grant of 14,000 shares of common stock in the form of restricted stock units as part of her annual equity compensation. The RSUs were approved on March 29, 2026 and became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan on June 4, 2026.
The RSUs vest in four approximately equal installments on March 29 of 2027, 2028, 2029, and 2030, assuming she remains in continuous service. Following this grant and an administrative correction that removed 3,332 shares from prior totals, she now directly holds 48,145 shares of common stock.
Assembly Biosciences director John G. McHutchison received a grant of stock options for 8,000 shares of Common Stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036. They vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders.
ASSEMBLY BIOSCIENCES, INC. director Susan Mahony received a grant of stock options covering 8,000 shares of common stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036.
The options vest, assuming continuous service, upon the earlier of June 4, 2027 or the date of the company’s 2027 annual meeting of stockholders. Following this grant, Mahony holds 8,000 stock options directly.
Assembly Biosciences director Lisa Johnson-Pratt received a grant of stock options for 8,000 shares of common stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036. They vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting. Following this grant, she holds 8,000 stock options directly.
ASSEMBLY BIOSCIENCES, INC. director Michael Houghton received a grant of stock options covering 8,000 shares of common stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036. They vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Houghton holds 8,000 stock options directly.
ASSEMBLY BIOSCIENCES, INC. director Gina Consylman received a grant of stock options covering 8,000 shares of common stock. The options have an exercise price of $24.11 per share and represent compensation rather than an open-market purchase.
The options vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Consylman holds 8,000 stock options directly, with an expiration date in 2036.
Assembly Biosciences, Inc. reported that director Anthony E. Altig received a grant of stock options to acquire 8,000 shares of Common Stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036.
These options vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Altig holds stock options for 8,000 underlying shares directly.
Assembly Biosciences, Inc. reported that its Principal Financial Officer and Principal Accounting Officer, Jeanette M. Bjorkquist, acquired 3,500 shares of common stock at no cost through a grant of restricted stock units. These RSUs represent 35% of her annual equity grant and became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan that increased the shares authorized under the plan. The RSUs vest in four approximately equal installments on March 29 of each year from 2027 through 2030, assuming she remains in continuous service. Following this grant, Bjorkquist directly holds 14,589 shares of common stock.
Assembly Biosciences Chief Scientific Officer awarded RSUs. Chief Scientific Officer William E. Delaney IV received a grant of 14,000 restricted stock units of common stock at no cash cost, representing 35% of his annual equity grant. The award was contingent on stockholder approval of an amendment to the company’s 2018 Stock Incentive Plan and became issuable after that approval on June 4, 2026. The RSUs vest in four approximately equal annual installments on March 29, 2027, 2028, 2029, and 2030, assuming continued service. Following this award, he directly holds 60,330 shares of common stock, including 688 shares acquired through the employee stock purchase plan.
ASSEMBLY BIOSCIENCES, INC. CEO and President Jason A. Okazaki received a grant of 50,750 shares of common stock in the form of restricted stock units at no cash cost. These RSUs were approved on March 29, 2026 and became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan on June 4, 2026.
The RSUs vest in four approximately equal annual installments on March 29, 2027, 2028, 2029, and 2030, subject to continued service. After this award, Okazaki directly holds 163,354 shares of common stock, including 688 shares acquired through the company’s Employee Stock Purchase Plan on May 14, 2026.
Gilead Sciences, Inc., a ten percent owner of Assembly Biosciences, Inc., reported receiving a grant or other acquisition of 471,698 shares of Common Stock on May 26, 2026 at $26.50 per share. After this award, Gilead directly holds 4,977,089 Assembly common shares.
Assembly Biosciences PFO and PAO Jeanette M. Bjorkquist reported a mix of equity grants and related share sales. She received a grant of 6,500 restricted stock units (RSUs), scheduled to vest in four equal installments on March 29 of 2027, 2028, 2029, and 2030, assuming continuous service. Footnotes state that RSUs represent 65% of her annual equity grant and that the remaining 35% of RSUs is contingent on stockholder approval of an amendment to the company’s 2018 Stock Incentive Plan to increase authorized shares. On March 30, 2026, she sold a total of 328 common shares in open-market transactions at weighted average prices of $26.6502 and $27.49 per share to cover tax withholding obligations under a mandatory sell-to-cover rule, described as a non-discretionary transaction. Following these transactions, she directly holds 11,089 common shares.
Assembly Biosciences Chief Manufacturing Officer Nicole S. White received a grant of 26,000 restricted stock units (RSUs) and completed a small mandated share sale to cover taxes. The RSUs vest in four equal installments on March 29 of each year from 2027 through 2030, subject to continuous service. Footnotes state that 35% of the RSUs are contingent on stockholder approval of an amendment to increase shares authorized under the company’s 2018 Stock Incentive Plan. To satisfy tax withholding from RSU vesting, White sold a total of 197 common shares in open-market “sell-to-cover” transactions, described as required by a Compensation Committee administrative rule rather than discretionary trading. Following these transactions, she directly holds 37,477 common shares.
Assembly Biosciences Chief Medical Officer Anuj Gaggar received an equity grant tied to company stock. The Form 4 reports a grant of 26,000 shares underlying restricted stock units that were awarded at no cash cost to him.
The RSUs vest in four equal installments on March 29 of 2027, 2028, 2029 and 2030, assuming he remains in continuous service. The award represents 65% of his annual equity grant, while the remaining 35% is contingent on stockholder approval of an increase in shares authorized under the company’s 2018 stock incentive plan. After this grant, he directly holds 28,000 shares, including 2,000 shares previously acquired through the employee stock purchase plan.
Assembly Biosciences granted Chief Scientific Officer William E. Delaney IV 26,000 restricted stock units (RSUs) on March 29, 2026. The RSUs vest in four equal annual installments on March 29, 2027, March 29, 2028, March 29, 2029, and March 29, 2030, assuming continuous service on each date.
The RSUs represent 65% of his annual equity grant, while the remaining 35% is contingent on stockholder approval of an amendment to the company’s 2018 Stock Incentive Plan to increase authorized shares. After this grant, Delaney directly holds 45,642 common shares, including 2,909 shares acquired through the employee stock purchase plan on May 14, 2025.
Assembly Biosciences CEO and President Jason A. Okazaki received a grant of 94,250 restricted stock units (RSUs) of common stock. The RSUs vest in four approximately equal installments on March 29 of each year from 2027 through 2030, assuming continuous service on each vesting date. The RSUs represent 65% of his annual equity grant, while the remaining 35% of RSUs are contingent on stockholder approval of an amendment to the company’s Amended and Restated 2018 Stock Incentive Plan to increase shares authorized under the plan. Following this award, Okazaki beneficially owns 111,916 shares, including 2,909 shares previously acquired under the company’s Employee Stock Purchase Plan.